In the vast majority of patients the administration of succinyleholine is not accompanied by clinically significant adverse reactions. In a minority of patients, however, undesired cardiovascular effects of variable magnitude and severity have been observed and recently reviewed, b-9 Information about the mechanisms producing these adverse reactions is sparse or lacking.
receptors produces attenuation of the norepinephrine release. In the majority of patients these opposing actions are balanced and the net result is small, variable, and of little clinical importance. An unbalanced response leading to clinical manifestations can be expected if the nvo types of the presynaptic choltnoceptors are differentially activated.
In the vast majority of patients the administration of succinyleholine is not accompanied by clinically significant adverse reactions. In a minority of patients, however, undesired cardiovascular effects of variable magnitude and severity have been observed and recently reviewed, b-9 Information about the mechanisms producing these adverse reactions is sparse or lacking.
The purpose of this article is threefold: I. To describe briefly the adverse cardiovascular effects of succinylcholine and their reputed causes.
II. To present the hypothesis that the adverse reactions to succinylcholine are attributable, at least in part, to the interaction between sueeinyleholine and the specific cholinergic receptors.
III. To interpret the effects noted under I in terms of the proposed hypothesis.
administration of succinylcholine (1 mg'kg-~). ~~ Initial bradycardia is followed by the return of the heart rate to normal (i.e., preinjection) or to slightly higher levels. In infants, bradycardia is observed after the intravenous jl but not after the intramuscular injection of succinylcholine. 12A3 Bradycardia in adults is more pronounced after the second or subsequent doses of suceinylcholine, ~4 especially if the time interval between the two doses is in the range of two to five minutes. ~5'~6 A slow intravenous infusion of succinylcholine is seldom accompanied by cardiovascular alterations. ~ 7.~ s
The mechanism leading to these cardiovascular effects of succinylcholine is not clear. Most reports attribute bradycardia to the stimulation of the muscarinic receptors present in the sino-atrial node. This can clearly not be the sole explanation since it does not account for the more frequent incidence of bradycardia either in children or after repeated injection. The claim that children are "relatively sympathicotonic individuals ''6 was not substantiated and is not convincing. Neither is the postulate that metabolites of succinylcholine (succinylmonocholine and choline) sensitize the heart to subsequent doses of succinylcholine L9 since intravenous infusion of equal or larger amounts of succinylcholine does not produce such "sensitization." Moreover, this proposal does not provide an explanation for bradycardia in children or for the relatively short time period when the administration of the second dose of succinylcholine is especially apt to cause bradycardia in adults. The fact that atropine, a muscarinic blocking agent, is effective for the prevention of the bradycardic response in clinical practice does not help clarify the pharmacologic problem. Atropine prevents activation of the cardiac muscarinie receptors and thus only permits an unopposed expression of the extant sympathetic activity.
Severe haemodynamic crises, including cardiac arrest, have been reported in patients with bums, tetanus, spinal cord transection, or lower motor neuron injury 2~ and, more recently, in a patient after irradiation. 2j Increased serum potassium has been observed frequently during these crises. 2~ Cardiovascular collapse has been conveniently ascribed to this hyperkalaemic response, sometimes even in the absence of documented hyperkalaemia. ~2 A mechanism leading to hyperkalaemia has been outlined for patients with lower motor neuron lesions (denervation) 2~ but not for the other clinical situations.
Pretreatment of patients with different pharmacologic agents is employed, with variable benefits, to attenuate adverse reactions to succinyleholine that are not related to the cardiovascular system. For this purpose a small dose of a non-polarizing muscle relaxant, 13-z5 lidocaine, 26"27 diazepam ~8-3~ or succinyleholine itself ("self-taming") 32 have been used. Conspicuously, the effects of such pretreatment on the cardiovascular effects of suecinylcholine were not tested. A small dose of d-tubocurarine was, however, reported to prevent bradycardia from the second dose of succinylcholine, 33.34 As an explanation, Mathias et al. 34 proposed the bradycardia represents the reflex response to stimulation of the baroreceptors by succinylcholine; d-tubocurarine would prevent this stimulation without affecting the heart directly. Nevertheless, this very attractive interpretation still does not explain why the second dose of succinylcholine causes bradycardia more often than does the first nor why bradycardia occurs more frequently in children.
II. Interaction of succinylcholine with cholinergic receptors: the proposed hypothesis
Statement of the hypothesis: Suecinylcholine produces a release of endogenous catecholamines. The interplay among the effects produced by the liberated catecholamines, the anaesthetic agent, and the pronounced hyperkalaemia (if present) detemaines the occurrence and the clinical pattern of the early adverse haemodynamic reactions. The presentation of the hypothesis will proceed from the description of the basic pharmacologic information about cholinoceptors and catecholamines, to the exposition of the hypothesis, and finally, to the interpretation of the previously reviewed clinical observations.
Cholinergic drugs and cholinoceptors
Succinylcholine causes a failure of neuromusc~llar transmission by interacting with the postsynaptic nicotinic receptor on the endplate. 3s The initial reaction is the depolarization of the cndplate (initial stimulation) followed by the inability of the endplate to respond to subsequent stimulation by aeetylcholine (muscle paralysis). This sequence of events -an initial stimulation and a subsequent inhibition -is also observed with some other drugs that interact with nicotinic receptors. Nicotine itself is the best known example of these agents and its very complex pharmacologic and toxic effects are due to such a biphasic reaction of the nicotinic receptors. 36 When administered to animals, nicotine produces muscle paralysis, a contracture of denervated skeletal muscles, and alterations in blood pressure and heart rate. 36"38 The similarity of these responses to those of succinylcholine is obvious. Interaction of nicotine with receptors in the autonomic ganglia and in the striated muscles, facilitation of ganglionic transmission, 39 and stimulation of the nicotinic receptors on the sensory terminals of the autonomic afferents ~7 account for many of these effects. Nicotine also elicits pharmacologic responses in isolated tissues devoid of ganglionic cells: nicotine or acetylcholine (the latter in the presence of atropine) produce both positive chrenotropie and positive inotropic effects in isolated heart preparations, 4~ contracture of the isolated spleen, 42 and constriction of the isolated middle ear artery of the rabbit. 43'44 All of these effects in isolated organs are explained by the nicotine-induced release of catecholamines, predominantly norepinephrine.
Taking the isolated rabbit heart preparation as a model, the following phenomena have been observed:
(a) The release of norepinephrine occurs as a burst immediately on exposure to a nicotinic agent. The release is short-lived even though perfusion with the agonist is continued ("explosive release"). 45 Norepinephrine, rather than its metabolic products, constitutes the major fraction of the tritiated compounds released from the rabbit atria prelabeled with SH-norepinephrine. 46 (b) The second dose of the same or of another nicotinic agonist shortly after the first dose results in an attenuated or an absent release of norepinephrineY (c) The release of norepinephrine is inhibited by pretreatment with a ganglionic blocking agent 4s'48 or d-tubocurarine 40, 49 Hexamethonium, however, does not inhibit norepinephrine release evoked by electrical nerve stimulation. 5~ (d) An initial exposure of the isolated tissues to a very small concentration of a nicotinic agonist does not cause a release of norepinephrine and yet it prevents such a release when the same tissues are subsequently exposed to higher concentrations of the agonist. 4~
(e) The release of norepinephrine is dependent on the presence of ionized calcium in the bathing solution. This is in contradistinction to the calciumindependent release of norepinephrine by tyramine.'~7 (f) Although the release of norepinephrine ceases on continuous exposure to a nicotinic agonist. subsequent electrical stimulation of the postganglionic sympathetic fibres to the isolated heart does produce the release of norepinephrine.5 ' Analogous findings have been observed in other isolated tissues. 44"~2-54
All of these findings in isolated organs and tissues were interpreted by postulating the existence of presynaptie nicotinic receptors on the postgan& lionic sympathetic terminals ( Figure 1 ). Stimulation of these receptors leads to a release of norepinephrine. Their inactivation, however, does not affect the release of norepinephrine evoked by physiologic stimuli traversing the postganglionic sympathetic fibres. The brief duration of norepinephrine release elicited by nicotinic agonists is attributed to a short lasting activation of the receptors and their subsequent conversion to an inactive state -desensitization. Very small concentrations of nicotinic agonists are postulated to convert the nicotinic receptors from an active (responsive) to a desensitized state without apparent previous activation. 54 In addition to these presynaptic nicotinic receptors, a large body of evidence has been accumulated to show the existence of presynaptic muscarinic receptors on the postgang[ionic sympathetic fibres. ~ Activation of these receptors inhibits the release of norepinephrine elicited either by nicotinic drugs s6 or by electrical stimulation of the postganglionic sympathetic fibres 57 ( Figure 1 ). Since acetyleholine stimulates both the nicotinic and the musearinic presynaptie receptors on the sympathetic terminals, pretreatment with atropine is required to elicit the maximal release of norepinephrine. 56 Atropine by itself has no effect on norepinephrine release elicited by electrical stimulation, s~ The presynapfic muscarinic inhibitory receptors are activated by a much lower concentration of a cholinergic agonist than are the presynaptic facilitory nicotinic receptors. 33 These muscarinic receptors also show a desensitization phenomenon. 58'~9 A direct comparison of durations of desensitizations of the two receptor types is not availab!e; there is some indication that the desensitization of the muscarinie receptors is shorterlasting. ~s-~9 
The hypothesis
Taken together, all of these previously reported observations permit a fresh look at the pharmacologic actions of suecinyleholine as a cholinergic agent. The hypothesis, explicitly stated earlier, is based on the following postulates:
(1) Succinylcholine is a cholinergic agent that, like acetylcholine, interacts with the muscarinic as well as with the nicotinic receptors. The efficacy of succinylcholine 6~ may be different at different receptor sites.
(2) Succinylcholine initially activates both the postsynaptie and presynaptic receptors of either type. The initial activation is followed by a period of reduced chemosensitivity of the receptors (desensitization). 6~ (3) Desensitization of the nicotinic receptors outlasts that of the muscarinic receptors (no experimental proof is presently available).
The hypothesis that suecinylcholit~e releases endogenous catecholamines is diagrammatically presented in Figure 2 . Two nicotinic receptors (one postsynaptic on the endplate of the skeletal muscle and the other presynaptic on the sympathetic nerve terminal) together with two muscafinic receptors (one postsynaptic on or around the sino-atrial node and the other presynaptic on the sympathetic nerve terminal) are simultaneously exposed to succinylcholine which is assumed to have been administered by an intravenous bolus injection. Interaction of all these receptors with succinylcholine produces a very brief activation. The activation is immediately followed by a period of insensitivity to chemical stimulation -most probably desensitization of the receptors. As postulated, the desensitization lasts longer for the nicotinic than for the muscarinic receptors. Clinically, activation of the nicotinic receptors on the end-plate is manifest as a brief period of skeletal muscle activity (fasciculation) and the subsequent period of desensitization as a flaccid paralysis. Interaction of succinyleholine with the cholinoceptors at the sympathetic terminals leads to a less well defined clinical picture and is clearly dependent on the relative extent of activation and inhibition at these sites. Initial activation of the nicotinic receptors on the sympathetic terminals in the myocardium, and elsewhere, causes the release of norepinephrine. Initial activation of the postsynaptic muscarinic receptors at the sine-atrial node produces bradycardia. The bradycardia is brief due to the counter-action of norepinephrine released by the activation of the presynaptic nicotinic receptors. The release of norepinephrine is, however, opposed by the activation of the presynaptic muscarinic receptors on the sympathetic terminals. Due to the mutually opposing effects resulting from the activation of these cholinoceptors by suceinylcholine, the net effect is small and variable.
DIAGRAM OF THE HYPOTHESIS
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In other words, succinylcholine usually produces balanced and clinically inconspicuous cardiovascular effects. If for whatever reasons -premedication, pharmacologic inhibition or anatomical underdevelopment of the individual receptors -one group of receptors is activated more than the other, an unbalanced and clinically manifest cardiovascular response to succinylcholine results.
Clinical correlates
Specific examples of the unbalanced haemodynamic responses to succinyleholine can now be given. It will be seen that these situations correspend to those described in the Introduction when succinylcholine was noted to produce adverse reactions.
(a) A second intravenous bolus injection of suecinylcholine might be expected to lead to an unbalanced response if succinylcholine is administered during the interval when (1) the muscarinic receptors hacve already recovered their full chemoreactivity, and (2) the desensitization of the nicotinic receptors still persists. The expected result is bradycardia (Figure 2 ). Such a "window" for the bradycardic effect of the second injection of succinylcholine is consistent with clinical observations. The bradyeardic response can be attributed to the activation of the postsynaptic muscarinie receptors around the sine-atrial node arid of the presynaptic musearinic receptors on the sympathetic terminals. The latter effect would attenuate the release of not'epinephrine even when such were to be elicited by physiologic regulatory mechanisms. This interpretation offers a plausible explanation for the observation that the intramuscular or intravenous administration of atropine before anaesthesia "did not protect against bradycardia or cardiac arrest after the second dose of suxamethonium. '62 (b) The bradycardie response to succinylcholine in infants and children indicates a deficient nicotinic response. The anatomic basis for this deficiency is seen in the lag of the development of the sympathetic terminals in the myocardium of newborn and young animals. 63"-65 Whereas the parasympathetic fibres to, and the postsynaptic muscarinic receptors of, the heart develop early, sympathetic terminals develop later; morphologic and pharmacologic studies 66"67 are in full conformity on this point. Norepinephrine stores in the heart during foetal development are present only in the "preterminal nerve trunks" that do not penetrate into the ventricuiar myocardium. 66 The mature type of sympathetic innervation and pharmacologic reactivity to agents that release norepinephrine from the sympathetic terminals are first seen at different postnatal intervals in different species. 63'6s (c) The so-called "self-taming" effect of succinylcholine 32 can be easily understood as an onset of desensitization of the cholinergic receptors without an apparent antecedent activation. This explanation accounts also for the minimal haemodynamic effects observed when succinylcholine is administered by slow infusion or by intramuscular injection rather than as a bolus intravenously. Both of these methods of succinylcholine administration result in a slow rate of interaction of suceinylcholine with the cholinergic receptors and, therefore, only minimal activation or none at all; the inactivation of the endplate receptors and, hence, muscle relaxation remain unaffected.
(d) Clinical situations most frequently associated with early haemodynamic crises after the administration of succinylcholine share an altered state of the sympathetic nervous system as their common denominator. The hypermetabolic state of a burned patient is attributed to the increased sympathetic activity 69 which, if extensive and prolonged, may lead to a complete exhaust,~on of the adrenergie system. 7~ In patients with tetanus, hypertensive crises and the frequent occurrence of arrhythmias indicate an increased activity of the sympathetic nervous system. 73 As expected, the hyperreacfivity is alleviated by appropriate use of adrenergic blockers and sedation. 74 Tetraplegic and, less so, paraplegic patients show supersensitivity to circulating ~drenergic agonists. 75, 76 This supersensitivity may be ascribed to the absence of funcfionally active postganglionic sympathetic fibres (sympathetic denervation). In addition, in these patients the control of the sympathoadrenal system is postulated to occur "through reflex spinal mechanisms uninhibited by supraspinal centers. ''77 Activation of the sympathetic nervous system was also observed in massively traumatized patients.78'79 Finally, irradiation has been shown to increase the demand for catecholamines and to deplete markedly their stores in the adrenal medulla, s~
The administration of sucdnylcholine to patients suffering from the conditions described can be assumed to lead to the release of endogenous catecholamines which might be very much different from that observed in normal patients. The two extremes, either an abnormally high release or an absent response, could easily lead to clinical crises. The following findings make it obvious that the interaction between the increased levels of catecholamines on one side and the increased levels of extracellular potassium and the anaesthetic agents on the other, is multifaceted:
(1) Catecholamines, especially epinephrine, cause an initial, brief hyperkalaemia followed by prolonged hyperkalaemia, s 1 -ss (2) In dogs anaesthetized with pentobarbitone, adverse haemodynamic effects of toxic doses of potassium given by infusion are ameliorated by catecholamines, a6,87 (3) In dogs during cyclopropane anesthesia Cmyocardial sensitization") epinephrine does not produce ventricular taehycardia if the concomitant hyperkalaemic response to epinephrine is prevented; s8 co-administration of potassium and epinephrine in these dogs, however, does produce cardiac irregularities.
Obviously, hyperkalaemia is but one biochemical change accompanying the administration of succinylcholine. As postulated, catecholamines released by succinylcholine might either produce effects on their own or modify the response to hyperkalaemia. It is the unbalanced interaction of succinylcholine with the cholinoceptors and the responses elicited by cateeholamines that lead to occasional haemodynamic crises in exceptional clinical situations.
IlL Discussion Any attempt to explain the events leading to haemodynamic crises after the administration of succinylcholine has to account for the following clinical observations: (a) Mild haemodynamic reactions or life-threatening crises occur only during the initial several minutes after the IV injection. (b) Clinically significant haemodynamic adverse effects occur after the intravenous administration of customary doses of suecinylcholine (about 1 mg.kg-J IV). The apparent lack of the dose-response relationship for these complications is well illustrated by considering patients with deficient or aberrant pseudocholinesterase: these patients are exposed to high blood levels of succinylcholine for prolonged periods of time and yet there are no reports about clinically detrimental haemodynamic effects of succinylcholine during the prolonged apnoea. The absence of such effects has not been stressed in the past. (c) Succinylcholine does not inevitably cause haemodynamic crises in all patients deemed to be at risk. So, for example, several reports document uneventful use of succinylcholine in bum patients 9~ and others document only an increased frequency of adverse reactions when compared to the control population. 93 Clearly, additional factors have to be considered as contributory in the occasional production of cardiac arrest.
Direct support for the presented hypothesis was recently obtained in anaesthetized patients. 94 Following induction of anaesthesia with thiopentone and maintenance with nitrous oxide and halothane, succinylcholine was injected intravenously and ventilation controlled using a mask and reservoir bag. Plasma levels of norepinephrine in arterial blood started to rise immediately after the injection of suecinylcholine, peaked at three minutes and subsequently declined to preinjection levels (tenth minute). Elevation of plasma levels of epinephrine was less marked. The data are in agreement with the notion that succinylcholine activates the presynaptie mcotmic receptors on the postganglionic sympathetic terminals. Their activation results in a sudden but brief release of norepinephrine. Since the major portion of the liberated norepinephrine is disposed of locally by the uptake into neuronal and extraneuronal tissues, plasma levels reflect only the overflow. 9.~,96 The wash-out from the tissues accounts for the relatively delayed appearance of the peak levels of norepinephrine in plasma. Once in the circulation, however, levels of norepinephrine decrease rapidly due to its very short initial half-lge in plasma (about 2 minutes). 9s Since norepinephrine is released locally in the tissues, it is clear that the plasma levels of the catecholamine would not necessarily show a direct quantitative relationship to the magnitude of its effects. This point becomes very important if one considers that sucr might cause release of norepinephrine directly in the myocardium. Many lines of evidence, both clinical and experimental, support the hypothesis that the release of endogenous catecholamines contributes significantly to the adverse effects of succinylcboline. In clinical practice, cardiac arrest, rather than the collapse of the peripheral circulation, is the principal finding. If resuscitative measures (cardiac massage~ are applied early, the crisis can usually be terminated after only a brief effort (e.g. 22) . The sudden but brief release of norepinephrine by succinylcholine and the very short half-life of the liberated catecholamine(s) are consistent with the underlying events in most situations. If, however, activation of the nicotinic receptors does not occur and, hence, there is no release of eatechotamines, direct stimulation of the post-synaptic muscarinic receptors by succinylcholine may lead to pronounced bradycardia and even cardiac arrest in asystole (as has been observed in infants). It is important to note that similar changes in the electrocardiographic T-wave can be produced by eatecholanfmes as well as by hyperkalacmia. 97-99 Adverse effects of catecholamines can be expected to be more pronounced in the presence of hypoxia, hypercarbia and inhalational anaesthetic agents that "sensitize" the myocardium to catecholamines. In addition, laryngoscopy, tracheal intubation (e.g. ~) and the transfer of the patient to the operating table soon "after intubation 92'93 represent further sympathetic stimulation. Premedication with large doses of antimuscarinic drugs (atropine and glycopyrolate) has been shown to increase the incidence of dysrhythrnias after succinylcholine-facilitared intubation. J~ This finding is easily understandable in terms of the proposed interaction of succinylcholine with presynaptic muscarinic and nicotinic receptors on the sympathetic terminals: blockade of the muscarinic receptors by atropine leaves the activation of the presynaptic nicotinic receptors unopposed and consequential. Clearly, many factors influence the clinical picture of the adverse reactions to succinylcholine either by causing an additional liberation of, or altering the response to, the catecholamines.
Several experimental studies are also in full concordance with the proposed hypothesis. In agreement with a previous report, j~ Tucker and Munson I~ found that the threshold arrhythmogenic dose of epinephrine in dogs under halothane anaes-thesia is markedly decreased by a preceding bolus injection of succinylcholine. The authors concluded only that succinylcholine "increases the arrhythmogenicity of epinephrine" during halothane anaesthesia. A different interpretation can now be offered. If, as presently hypothesized, succinylcholine releases endogenous catecholamines, it is to be expected that the arrhythmogenic dose of exogenous epinephrine will be proportionately reduced. Lack of arrhythmogenic effects of succinylcholine reported by Wong etal. ~04 is most likely due to the different mode of sueeinylcholine administration (infusion).
Norepinephrine may be released from its stores by mechanisms otber than stimulation of the presynaptic nicotinic receptors. Independent of the nature of the release mechanism, however, the cardiac manifestations during halothane mlaesthesia should be similar~ This notion has been confirmed. Experiments of Condouris etal. 97,t~176 demonstrate that the initial release of norepinephrine produced by tyramine, bretylium or guanethidine precipitates ventricular arrhythmias in cats during halothane anaesthesia. Plasma potassium levels were not determined.
There are two clinical areas in which the hypothesis may lead to reinterpretation of available data. First, the release of norepinephrine from the sympathetic terminals induced by activation of the presynaptic nicotinic receptors can be attenuated by a number of drugs. 47 In the context of the present discussion, inhibition produced by opiates, to3 barbiturates, lo8 and by local and inhalational anaesthetic agents 1~ t~ is noteworthy. These findings indicate that the induction of anaesthesia with ultra-short acting barbiturates and the maintenance of anaesthesia with inhalational anaesthetic agents may not only attenuate the hyperkalaemia response to succinylcholine 112,1,3 but may also decrease the succinylcholine-induced release of catecholamines. Since all the modalities used to reduce the succinylcholineinduced fasciculation have also been shown to attenuate the release of norepinephrine elicited by stimulation of the nicotinic receptors in vitro, a similar response might be expected in vivo under clinical conditions. The recently presented clinical findings on the effects of precurarization on the prolongation of the QT interval produced by succinylcholine 1 ~ 4 can now be explained using the proposed model. Second, catecholamines produce responses on the dencrvated muscles t t5,~:6 as well as on the extraocular muscles 115 which are akin to those observed clinically after succinylcholine. Whether the effect of succinylcholine on these structures is a direct one or one indirectly facilitated by catecholamines remains to be examined.
Concluding remarks
The presented hypothesis offcrs an explanation for many clinical observations that have been difficult 1o understand. In pharmacologic terms, the hypothesis presents succinylcholine as a rather unique drug. The singularity of succinylcholine, as discussed here, is based on its transient activation and subsequent desensitization of the presynaptic cholinergic receptors on the sympathetic nerve terminals; no other drug in clinical use today is known to act similarly. Thus far, all published discussions of the interaction between succinylcholine and the nicotinic receptors have been limited to the consideration of the postsynaptic receptors localized either at the endplate or in the autonomic ganglia, l Jr The novel model proposed here -interaction between succinylcholine and the presynaptic cholinoceptors on the sympathetic terminals -is strongly supported by data from experiments in animals; direct support in humans under clinical conditions is necessary but may be difficult to obtain. 
